ALS-PDC1
MCID: AMY066
MIFTS: 54

Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex (ALS-PDC1) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Aliases & Descriptions for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex:

Name: Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 54
Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 54 50 66 29
Guam Disease 50 56 66
Parkinsonian Disorders 42 69
Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex, Susceptibility to 13
Amyotrophic Lateral Sclerosis, Parkinsonism/dementia Complex of Guam 50
Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia of Guam Syndrome 56
Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex of Guam 66
Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 56
Amyotrophic Lateral Sclerosis, Guam Form 69
Parkinsonism-Dementia-Als Complex 56
Lytico-Bodig Disease 56
Als/pdc of Guam 66
Als-Pdc1 66
Pdals 56

Characteristics:

HPO:

32
amyotrophic lateral sclerosis-parkinsonism/dementia complex:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

OMIM 54 105500
Orphanet 56 ORPHA90020
ICD10 via Orphanet 34 G12.2
MedGen 40 C0543859

Summaries for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

OMIM : 54 Amyotrophic lateral sclerosis-parkinsonism/dementia complex of Guam is a neurodengenerative disorder with unusually... (105500) more...

MalaCards based summary : Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex, also known as amyotrophic lateral sclerosis-parkinsonism/dementia complex 1, is related to parkinson disease 7, autosomal recessive early-onset and dementia, and has symptoms including muscle weakness, amyotrophic lateral sclerosis and muscle cramps. An important gene associated with Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex is TRPM7 (Transient Receptor Potential Cation Channel Subfamily M Member 7), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Chks in Checkpoint Regulation. The drugs Acetylcholine and Dopamine have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and growth/size/body region

UniProtKB/Swiss-Prot : 66 Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1: A neurodegenerative disorder characterized by chronic, progressive and uniformly fatal amyotrophic lateral sclerosis and parkinsonism- dementia. Both diseases are known to occur in the same kindred, the same sibship and even the same individual.

Wikipedia : 71 Lytico-bodig, sometimes spelled Lytigo-bodig, is the name of a disease in the language of Chamorro. It... more...

Related Diseases for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Diseases related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Related Disease Score Top Affiliating Genes
1 parkinson disease 7, autosomal recessive early-onset 12.0
2 dementia 10.6
3 lateral sclerosis 10.6
4 deafness, autosomal recessive 101 10.2 MAPT RPS27A SNCA
5 lower gum cancer 10.2 LRRK2 RPS27A SNCA
6 transient neonatal myasthenia gravis 10.2 LRRK2 SNCA
7 benign partial epilepsy with secondarily generalized seizures in infancy 10.2 LRRK2 MAPT SNCA
8 cyprus facial neuromusculoskeletal syndrome 10.1 MAPT RPS27A SNCA
9 craniofacial and skeletal defects 10.1 MAPT RPS27A TARDBP
10 juvenile amyotrophic lateral sclerosis with dementia 10.1 APP MAPT SNCA
11 plekhm1-related autosomal recessive osteopetrosis 10.1 LRRK2 MAPT PARK7 SNCA
12 riedel's fibrosing thyroiditis 10.1 LRRK2 MAPT SNCA TARDBP
13 atrial septal defect 9 10.1 APP MAPT SNCA
14 autism 19 10.1 LRRK2 MAPT RPS27A SNCA
15 parkinson disease 6, early onset 10.1 LRRK2 PARK7 PINK1
16 spinal cord glioma 10.1 C9orf72 SMN1 TARDBP
17 multiple system atrophy 10.1 PARK7 PINK1 SNCA
18 clpb deficiency 10.0 C9orf72 LOC109504728
19 systemic lupus erythematous, association with 6 10.0 ALS2 TARDBP
20 vaginal spindle cell epithelioma 10.0 APP MAPT SOD2
21 adult mesenchymal chondrosarcoma 10.0 C9orf72 MAPT TARDBP
22 allergic bronchopulmonary aspergillosis, familial 10.0 APP MAPT RPS27A TARDBP
23 pancreatic solid pseudopapillary carcinoma 10.0 C9orf72 MAPT TARDBP
24 acne inversa, familial, 3 10.0 MAPT PCSK1N RPS27A SNCA TARDBP
25 mitochondrial dna depletion syndrome 3 10.0 C9orf72 MAPT SNCA TARDBP
26 severe congenital nemaline myopathy 10.0 C9orf72 MAPT RPS27A TARDBP
27 andersen syndrome 10.0 C9orf72 MAPT RPS27A TARDBP
28 chorioamnionitis 10.0 ALS2 C9orf72 TARDBP
29 lethal congenital contracture syndrome 8 10.0 LRRK2 PARK7 PINK1 SNCA
30 thrombosis 10.0 LRRK2 PARK7 PINK1 SNCA
31 angina pectoris 10.0 C9orf72 MAPT TARDBP
32 osteogenesis imperfecta, type vi 9.9 C9orf72 TARDBP
33 autoimmune disease of urogenital tract 9.9 C9orf72 LRRK2 MAPT SNCA TARDBP
34 meier-gorlin syndrome 5 9.9 APP LRRK2 MAPT PARK7 RPS27A SNCA
35 rubinstein-taybi syndrome 2 9.8 PINK1 PRKN
36 spink1-related hereditary pancreatitis 9.8 LRRK2 MAPT PARK7 PRKN SNCA
37 epithelioid type angiomyolipoma 9.7 APP LRRK2 MAPT PINK1 SNCA TARDBP
38 eumycotic mycetoma 9.7 APP C9orf72 LRRK2 MAPT SNCA TARDBP
39 ceroid lipofuscinosis, neuronal, 1 9.7 LRRK2 PARK7 PINK1 PRKN SNCA
40 trichothiodystrophy 3, photosensitive 9.7 LRRK2 PARK7 PINK1 PRKN SNCA
41 klippel-feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism 9.7 LRRK2 PARK7 PINK1 PRKN SNCA
42 dystonia 9.6
43 ataxia 9.6
44 autonomic dysfunction 9.6
45 brain dopamine-serotonin vesicular transport disease 9.6
46 focal dystonia 9.6
47 mucopolysaccharidosis iv 9.6 ALS2 C9orf72 MAPT RPS27A SMN1 SOD2
48 cavernous hemangioma 9.6 LRRK2 MAPT PARK7 PINK1 PRKN SNCA
49 hemochromatosis, type 2a 9.4 LRRK2 MAPT PARK7 PINK1 PRKN RPS27A
50 coenzyme q10 deficiency, primary, 1 9.4 APP LRRK2 MAPT PARK7 PRKN RPS27A

Graphical network of the top 20 diseases related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex:



Diseases related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Symptoms & Phenotypes for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Symptoms by clinical synopsis from OMIM:

105500

Clinical features from OMIM:

105500

Human phenotypes related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex:

32 (show all 7)
id Description HPO Frequency HPO Source Accession
1 muscle weakness 32 HP:0001324
2 amyotrophic lateral sclerosis 32 HP:0007354
3 muscle cramps 32 HP:0003394
4 dementia 32 HP:0000726
5 abnormal lower motor neuron morphology 32 HP:0002366
6 parkinsonism 32 HP:0001300
7 bulbar palsy 32 HP:0001283

UMLS symptoms related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex:


tremor, bradykinesia, abnormality of extrapyramidal motor function, symptoms, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 ALS2 APP C9orf72 LRRK2 MAPT PARK7
2 growth/size/body region MP:0005378 10.15 SOD2 TARDBP TRPM7 PINK1 PRKN SNCA
3 cellular MP:0005384 10.14 APP C9orf72 LRRK2 MAPT PARK7 PINK1
4 homeostasis/metabolism MP:0005376 10.13 ALS2 APP C9orf72 LRRK2 MAPT PARK7
5 immune system MP:0005387 10 ALS2 APP C9orf72 LRRK2 MAPT PINK1
6 mortality/aging MP:0010768 9.93 ALS2 APP C9orf72 LRRK2 MAPT PINK1
7 nervous system MP:0003631 9.73 C9orf72 LRRK2 MAPT PARK7 PINK1 PRKN
8 no phenotypic analysis MP:0003012 9.28 APP C9orf72 LRRK2 MAPT PINK1 PRKN

Drugs & Therapeutics for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Drugs for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 452)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
2
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
4
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
5
Nicotine Approved Phase 4,Phase 2,Phase 1 54-11-5 942 89594
6
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1 136236-51-6 3052776
7
Bromocriptine Approved, Investigational Phase 4,Phase 3 25614-03-3 31101
8
Pramipexole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104632-26-0 59868 119570
9
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 91374-20-8, 91374-21-9 5095 497540
10
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
11
Amantadine Approved Phase 4,Phase 2,Phase 3,Phase 1 768-94-5 2130
12
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
13
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1 28860-95-9 34359 38101
14
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130929-57-6 5281081
15 Piracetam Approved Phase 4,Phase 2 7491-74-9
16
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2 41372-20-7, 58-00-4 6005
17
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
18
Armodafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 112111-43-0
19
Modafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 68693-11-8 4236
20
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3 68291-97-4 5734
21
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
22
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
23
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
24
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
25
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
26
Ziprasidone Approved Phase 4 146939-27-7 60854
27
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
28
Methylphenidate Approved, Investigational Phase 4,Phase 2,Early Phase 1 113-45-1 4158
29
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
30
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
31
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
32
Trimethobenzamide Approved Phase 4,Phase 1 138-56-7 5577
33
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
34
Fluoxetine Approved, Vet_approved Phase 4,Phase 3 54910-89-3 3386
35
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23651-95-8 443940
36
Mirabegron Approved Phase 4 223673-61-8
37
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
38
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
39
Suvorexant Approved Phase 4 1030377-33-3
40
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 73-31-4 896
41
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 10883523 5280795
42
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
43 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1
44 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1
45 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Phase 1
46 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 incobotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1
48 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1
50 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1841)
id Name Status NCT ID Phase
1 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4
2 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4
3 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
4 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
5 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4
6 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
7 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4
8 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4
9 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4
10 Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease Unknown status NCT01673724 Phase 4
11 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4
12 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4
13 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4
14 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4
15 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4
16 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4
17 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
18 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4
19 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism Completed NCT00331825 Phase 4
20 Stalevo in Early Wearing-Off Patients Completed NCT00125567 Phase 4
21 Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Completed NCT00888186 Phase 4
22 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4
23 Antipsychotic Response in Schizophrenia Completed NCT00018668 Phase 4
24 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4
25 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease Completed NCT01662414 Phase 4
26 Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY) Completed NCT00892047 Phase 4
27 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4
28 Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK) Completed NCT00632762 Phase 4
29 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4
30 Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease Completed NCT01313845 Phase 4
31 Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease Completed NCT00153972 Phase 4
32 Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off. Completed NCT00247247 Phase 4
33 Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II) Completed NCT00914095 Phase 4
34 D-serine Adjuvant Treatment for Parkinson's Disease Completed NCT00215904 Phase 4
35 Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease Completed NCT01032486 Phase 4
36 Donepezil to Treat Dementia in Parkinson's Disease Completed NCT00030979 Phase 4
37 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4
38 Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy Completed NCT01782222 Phase 4
39 Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off Completed NCT00391898 Phase 4
40 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4
41 Mild Cognitive Impairment in Parkinson's Disease Completed NCT01519271 Phase 4
42 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4
43 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Completed NCT01049984 Phase 4
44 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) Completed NCT00321854 Phase 4
45 A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease Completed NCT01485172 Phase 4
46 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4
47 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4
48 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4
49 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4
50 Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States Completed NCT00143026 Phase 4

Search NIH Clinical Center for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: parkinsonian disorders

Genetic Tests for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Genetic tests related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex:

id Genetic test Affiliating Genes
1 Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex 1 29

Anatomical Context for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Publications for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Articles related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex:

id Title Authors Year
1
C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. ( 23588498 )
2013
2
TRPM7 is not associated with amyotrophic lateral sclerosis-parkinsonism dementia complex in the Kii peninsula of Japan. ( 19405049 )
2010
3
Mutation analyses in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, Japan. ( 18759352 )
2008
4
Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). ( 18843496 )
2008
5
Atypical parkinsonism of Japan: amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): an update. ( 16092099 )
2005
6
Amyotrophic lateral sclerosis/parkinsonism dementia complex: transgenic mice provide insights into mechanisms underlying a common tauopathy in an ethnic minority on Guam. ( 12093078 )
2002
7
Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes. ( 8834536 )
1996
8
Identification of phosphorylation sites in PHF-TAU from patients with Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex. ( 8858002 )
1996
9
Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. ( 7717459 )
1995

Variations for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Expression for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Search GEO for disease gene expression data for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex.

Pathways for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

GO Terms for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

Cellular components related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.88 APP PARK7 PINK1 PRKN SNCA
2 neuronal cell body GO:0043025 9.81 ALS2 LRRK2 MAPT SNCA
3 neuron projection GO:0043005 9.63 ALS2 APP LRRK2 PARK7 PRKN SMN1
4 cell body GO:0044297 9.61 MAPT PARK7 PINK1
5 terminal bouton GO:0043195 9.58 APP LRRK2 SNCA
6 inclusion body GO:0016234 9.49 LRRK2 SNCA
7 astrocyte projection GO:0097449 9.37 APP PINK1
8 growth cone GO:0030426 9.35 ALS2 APP LRRK2 MAPT SNCA
9 Lewy body GO:0097413 9.32 PINK1 PRKN
10 axon GO:0030424 9.17 ALS2 APP LRRK2 MAPT PARK7 PINK1
11 cytoplasm GO:0005737 10.1 ALS2 APP C9orf72 LRRK2 MAPT PARK7
12 extracellular space GO:0005615 10 APP C9orf72 LRRK2 PCSK1N RPS27A SNCA

Biological processes related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.97 APP PRKN RPS27A SNCA
2 negative regulation of gene expression GO:0010629 9.93 MAPT PARK7 PINK1 PRKN TARDBP
3 autophagy GO:0006914 9.92 C9orf72 LRRK2 PARK7 PINK1 PRKN
4 macroautophagy GO:0016236 9.89 PINK1 PRKN RPS27A
5 locomotory behavior GO:0007626 9.87 ALS2 APP PRKN SOD2
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 PARK7 PINK1 SNCA
7 negative regulation of neuron apoptotic process GO:0043524 9.85 PARK7 PINK1 PRKN SNCA SOD2
8 adult locomotory behavior GO:0008344 9.81 APP PARK7 PRKN SNCA
9 regulation of autophagy GO:0010506 9.8 C9orf72 LRRK2 MAPT PRKN
10 synapse organization GO:0050808 9.79 APP MAPT SNCA
11 negative regulation of neuron death GO:1901215 9.78 LRRK2 PARK7 PRKN SNCA
12 mitochondrion organization GO:0007005 9.77 LRRK2 PARK7 PINK1 PRKN SOD2
13 regulation of reactive oxygen species metabolic process GO:2000377 9.75 PINK1 PRKN SNCA
14 synaptic transmission, dopaminergic GO:0001963 9.73 PARK7 PRKN SNCA
15 regulation of dopamine secretion GO:0014059 9.72 PRKN SNCA
16 regulation of neuron death GO:1901214 9.72 LRRK2 SNCA
17 respiratory electron transport chain GO:0022904 9.72 PINK1 SOD2
18 synaptic transmission, glutamatergic GO:0035249 9.72 ALS2 PRKN
19 regulation of neurotransmitter secretion GO:0046928 9.72 PRKN SNCA
20 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.72 LRRK2 PARK7 PRKN
21 negative regulation of protein phosphorylation GO:0001933 9.72 LRRK2 PARK7 PRKN SNCA TARDBP
22 regulation of protein ubiquitination GO:0031396 9.71 PINK1 PRKN
23 positive regulation of mitochondrial fission GO:0090141 9.71 PINK1 PRKN
24 cellular response to dopamine GO:1903351 9.71 LRRK2 PRKN
25 removal of superoxide radicals GO:0019430 9.71 SOD2 SOD3
26 regulation of mitochondrial membrane potential GO:0051881 9.71 PARK7 PINK1 PRKN SOD2
27 regulation of mitochondrion organization GO:0010821 9.7 PINK1 PRKN
28 microglial cell activation GO:0001774 9.7 MAPT SNCA
29 dopamine metabolic process GO:0042417 9.7 PRKN SNCA
30 supramolecular fiber organization GO:0097435 9.7 MAPT SNCA
31 negative regulation of macroautophagy GO:0016242 9.69 LRRK2 PINK1
32 negative regulation of oxidative stress-induced neuron death GO:1903204 9.69 PARK7 PINK1
33 positive regulation of peptidase activity GO:0010952 9.69 APP PINK1
34 negative regulation of autophagosome assembly GO:1902902 9.68 LRRK2 PINK1
35 mitophagy in response to mitochondrial depolarization GO:0098779 9.68 PINK1 PRKN
36 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.68 LRRK2 PARK7
37 positive regulation of mitophagy GO:1903599 9.67 PARK7 PRKN
38 intracellular distribution of mitochondria GO:0048312 9.66 LRRK2 MAPT
39 regulation of locomotion GO:0040012 9.66 LRRK2 SNCA
40 amyloid fibril formation GO:1990000 9.65 APP MAPT
41 hydrogen peroxide metabolic process GO:0042743 9.65 PARK7 SOD2
42 cellular response to toxic substance GO:0097237 9.65 PINK1 PRKN
43 regulation of mitochondrial fission GO:0090140 9.64 LRRK2 MAPT
44 regulation of protein targeting to mitochondrion GO:1903214 9.64 PINK1 PRKN
45 protein localization to mitochondrion GO:0070585 9.63 LRRK2 PRKN
46 cellular response to manganese ion GO:0071287 9.63 LRRK2 PRKN
47 negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway GO:1903377 9.62 PARK7 PRKN
48 negative regulation of mitochondrial fission GO:0090258 9.61 MAPT PINK1
49 regulation of cellular response to oxidative stress GO:1900407 9.61 PINK1 PRKN
50 dopamine uptake involved in synaptic transmission GO:0051583 9.61 PARK7 PRKN SNCA

Molecular functions related to Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.78 LRRK2 MAPT PRKN TRPM7
2 copper ion binding GO:0005507 9.54 PARK7 SNCA SOD3
3 phospholipase binding GO:0043274 9.46 PRKN SNCA
4 ubiquitin-specific protease binding GO:1990381 9.43 PARK7 PRKN
5 enzyme binding GO:0019899 9.43 APP MAPT PARK7 PRKN SNCA SOD2
6 peptidase activator activity GO:0016504 9.4 APP PINK1
7 tubulin binding GO:0015631 9.33 LRRK2 MAPT PRKN
8 superoxide dismutase activity GO:0004784 9.32 SOD2 SOD3
9 identical protein binding GO:0042802 9.28 APP LRRK2 MAPT PARK7 PRKN SMN1
10 cuprous ion binding GO:1903136 9.26 PARK7 SNCA

Sources for Amyotrophic Lateral Sclerosis-Parkinsonism/dementia Complex

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....